echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lost millions of dollars!

    Lost millions of dollars!

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationFan Dongdong

    A few days ago, US healthcare and health plan provider Kaiser Permanente has filed a lawsuit against drug maker Merck, claiming that the company’s "paid delay" plan caused it to lose millions of dollars
    .

    In an article in the San Francisco Business Times, Kaiser claimed that Merck was suspected of delaying the launch of Zetia and Vyotorin generic drugs by paying fees to generic drug manufacturers
    .


    Both of these native drugs are relatively high-priced, best-selling cholesterol drugs


    According to reports, Kaiser filed a lawsuit against Merck in the San Francisco Superior Court in June, and the case was later transferred to the U.
    S.
    District Court
    .


    Zetia (ezetimibe) was originally approved by the U.


    Kaiser Permanente is a non-profit organization with more than 12 million members in different states in the United States and 9 million members in California
    .


    Kaiser Permanente claimed that Merck’s postponement of the listing of generic drugs has caused "millions of dollars" in losses to the company and its members


    Pay-for-delay (pay-for-delay) is also known as reverse payment, because this delay delays the marketing of certain types of drugs, so that more expensive products of the same type can continue to dominate the market, and the healthcare industry is not welcome This approach
    .


    Pharmaceutical manufacturers usually adopt this approach in order to have enough time to continue to make high profits before cheaper generic drugs are on the market


    According to data from the US Federal Trade Commission (FTC), paid delays in operations have increased the cost of drugs for consumers and taxpayers in the United States by approximately US$3.
    5 billion each year
    .


    Since 2001, the regulator has also been actively filing lawsuits to stop this anti-competitive practice


    Merck has not yet commented on the legal dispute with Kaiser


    Reference: vKaiser Sues Merck, Generic Drug Firm Over Millions in Losses Due to Alleged "Pay-for-Delay" Scheme

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.